Merck (MRK), known as MSD outside of the United States and Canada, announced that the European Commission, or EC, has approved CAPVAXIVE, or ...

A comprehensive study from Karolinska Institutet shows that people with fatty liver disease have almost twice the mortality ...

Blog posts represent the views of CFR fellows and staff and not those of CFR, which takes no institutional positions. Most of the major U.S. pharmaceutical companies (AbbVie, Amgen, Bristol Myers ...

This guide covers all the logo design rules, best practices, tips, examples, and more to equip you with the knowledge for crafting brilliant logos. Logos are one of the most vital elements of any ...

MSD has invested $12bn in US capital since 2018. Credit: Katherine Welles/Shutterstock. MSD has opened a $1bn facility in Durham, in the US state of North Carolina, to increase vaccine manufacturing ...

A dispute over a microscopic enzyme is threatening Merck & Co. plans to sell a new version of Keytruda, the cancer drug that generates nearly half of the company’s sales. Merck has been tweaking ...

American pharma firm AbbVie is taking NHS England to court over a procurement process aimed to help England become the first country in the world to eradicate the hepatitis C virus (HCV).

Open innovation in medical and pharmaceutical research has grown steadily over the last decade. However, the performance of the published literature in terms of the scientific impact and gaining ...

Sign up for the Slatest to get the most insightful analysis, criticism, and advice out there, delivered to your inbox daily. Just nine weeks after UnitedHealthcare ...

With a thrust on strong operations over the past decade, Indian pharma production has outpaced global growth by over two times. Image: Sanjay Rawat India’s pharmaceutical sector is at a tipping point ...

Expertise from Forbes Councils members, operated under license. Opinions expressed are those of the author. 2025 is going to be a big year for AI adoption in pharma. By now, most life science ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.